Team

Mr. Cragg is the Managing Partner and a co-founder of Trevi Health Capital. Mr. Cragg has over 17 years of investment and advisory experience in the healthcare sector. Mr. Cragg’s investment experience includes behavioral health, clinical labs, clinical research organizations, eClinical, medical devices and urgent care. Mr. Cragg has considerable experience in building healthcare companies, overseeing corporate strategy & M&A and raising debt & equity capital. Mr. Cragg was previously an investment banker at Groton Partners, a merchant banking firm and, prior to that, a member of the Healthcare & Life Sciences Group at Wasserstein Perella and Prudential Vector Healthcare. Mr. Cragg has advised or invested in over $2 billion of equity & debt financings and $14 billion of M&A transactions. Mr. Cragg received a B.A., magna cum laude, from the University of St. Thomas. Mr. Cragg currently serves, or has served, as a director of AGI Dermatics, CareWell Urgent Care, Deep Vein Medical, Manhattan Physicians Laboratories and MedAvante.

Dr. Brown is a Partner of Trevi Health Capital. Dr. Brown has more than 25 years of experience in the healthcare sector as a successful strategist, operator, and dealmaker, and has led transactions worth a combined $9.9bn. Trained as a chemist, Dr. Brown started his career with The Upjohn Company, later moving to SmithKline Beecham, working in the field of drug metabolism and pharmacokinetics. Dr. Brown joined Phoenix International Life Sciences, a high-growth contract research organization (CRO), where he served as general manager responsible for operations in drug discovery and preclinical development. Following the successful sale of Phoenix International to MDS Inc., Dr. Brown assumed general management responsibility for MDS’ operations in preclinical drug development. Dr. Brown was appointed to the Executive Committee of MDS Pharma Services, and helped drive MDS into the top-5 global CRO rankings. In 2006, Dr. Brown joined Covance as global head of strategy and corporate development, and was appointed a member of the Executive Committee. At Covance, Dr. Brown executed 19 transactions, including the CRO industry’s largest strategic pharma partnership with Sanofi-Aventis valued at $2.2bn and the strategic sale of Covance to LabCorp for $6.2bn. Dr. Brown received bachelor and doctoral degrees from the University of Oxford, and was a Fellow at MIT. Dr. Brown currently serves, or has served, as a director of MedAvante Inc., BioAxone Biosciences Inc., LifeBlood Corporation, and CytoVas Inc.

Mr. Cimino is a Partner of Trevi Health Capital. Mr. Cimino was Executive Vice President and Group President Clinical Development and Commercialization Services at Covance. Mr. Cimino oversaw global operations in 60+ countries for Clinical Pharmacology, Early Clinical Development, Phase II/IV Clinical Development, Commercialization Services, as well as Covance’s Molecule Development Group. Mr. Cimino was a member of the company’s Operating Committee, Executive Committee and Benefits Committee. Mr. Cimino also directed corporate strategy and reported directly to the Chairman and Chief Executive Officer. Mr. Cimino joined Covance in December 2003. Under Mr. Cimino’s leadership, Covance’s Clinical Development Services business grew considerably, increasing in scale, profitability, size, and strategic service capabilities during his tenure. Prior to joining Covance, Mr. Cimino held several senior management positions during his 20-year career at Eastman Kodak. Most notably, he served as General Manager and Corporate Vice President, Americas, Health Imaging Group, where he was instrumental in the digital transformation of Kodak’s second-largest business, now Carestream Health Inc. Mr. Cimino has served, as a director for BioClinica as a public company and non-executive Chairman of MedAvante. He holds a Bachelor of Science degree in biology from the State University of New York at Geneseo.

Mr. Fink is an advisor and co-founder of Trevi Health Capital. Mr. Fink was previously a member of the Healthcare and Life Sciences Group at Dresdner Kleinwort Wasserstein, where he helped lead the firm’s medical technology effort, advising corporate clients on mergers & acquisitions and capital markets transactions. He began his career as a corporate lawyer at Paul, Weiss, Rifkind, Wharton & Garrison in New York. Mr. Fink received an A.B., magna cum laude, from Columbia College (where he was elected to Phi Beta Kappa) and a J.D. from Columbia School of Law. Mr. Fink is a member of the Board of Directors of the Alumni Association of Columbia College and the Street Squash Organization.

Mr. Robbins is an advisor and co-founder of Trevi Health Capital. After beginning his career as a corporate lawyer at Cahill Gordon & Reindel, he served as a strategic advisor to Elan Corporation, plc and as an advisor to the board of directors of Barr Pharmaceuticals in connection with the formation of Commerce Health Ventures, a healthcare investment fund in which he later served as a partner. Mr. Robbins serves as a board member of Trevi portfolio companies Paradigm Spine, Optovue and Home Skinovations, as well as Bally Technologies, Inc. (NYSE Arca: BYI), a diversified gaming and technology company, and previously Medisys plc; and is chairman of the board of trustees of the McCarton Foundation and School (addressing autism and developmental disabilities) and a member of the steering committee for the NYU Langone Comprehensive Epilepsy Center. He previously served as a board member for Columbia University Medical School’s Science and Technology Council and Connecticut Innovations life sciences seeder fund. Mr. Robbins has served as an assistant adjunct professor at the Benjamin N. Cardozo Law School, where he has taught courses in corporate finance. Mr. Robbins is a graduate of the Wharton School of the University of Pennsylvania, magna cum laude, and New York University School of Law.

Strategic Partners

Isaac Kaye built Norton Healthcare Limited, a UK generic pharmaceutical company, which was acquired by Ivax Corporation in 1990. Subsequent to the merger, Mr. Kaye continued to lead Norton, as Deputy Chief Executive Officer and Vice Chairman of Ivax, which was later sold to Teva Pharmaceutical Industries in 2006 for $7.4 billion. Mr. Kaye has also been active in promoting Israel-based technology and innovation. He was a co-founder of Israel Healthcare Ventures, a leading Israel-based venture capital firm, and established the Kaye Innovation Awards to encourage and recognize technological achievements at the Hebrew University of Jerusalem. Mr. Kaye is a member of the Board of Directors of Flynn Pharma.

Donald Panoz has over 40 years of healthcare operating and investing experience. Dr. Panoz founded Mylan Laboratories in 1960 and served as its President until 1969. He subsequently founded Elan Corporation in 1969 and served as its Chairman and CEO until 1996. Dr. Panoz currently serves or has served on the Board of Directors of Mylan, Elan, Sicor, Warner Chilcott and Sequitor Medical Technologies. Additionally, he has developed and headed global businesses in hospitality, real estate and community development and automotive racing, and has formed, invested in and monetized numerous development-stage companies in healthcare, technology and environmentally friendly technology.

Marvin Samson was formerly Group Vice President – Worldwide Injectables of Teva, previously having served as CEO and a member of the Board of Directors of Sicor. He is an expert in injectable manufacturing and delivery systems and was a founder and CEO of Elkins-Sinn (now a division of Baxter Healthcare) and Marsam Pharmaceuticals. He is the founder and CEO of Samson Medical Technologies, a privately held company providing hospital and alternate site pharmacists with injectable drug delivery systems and programs. Mr. Samson is Chairman of The University of Sciences Board of Trustees and serves on the Board of Directors of Trevi portfolio company Flynn Pharma. Mr. Samson served as chairman of the board and CEO of Qualitest Pharmaceuticals from 2007 until purchase by Endo Pharmaceuticals in late 2007 and as the chairman of the Generic Pharmaceutical Industry Association from 1997 to 2000. Mr. Samson is the holder of five U.S. patents pertaining to pharmaceutical manufacturing.

Steven Kaye is a founding partner of Israel Healthcare Ventures LP, a venture capital firm that focuses on medical technologies, pharmaceuticals and diagnostics. He is a partner in Baystone Associates Ltd., a London-based investment management company. Mr. Kaye served in a variety of roles and ultimately as Director of Strategic Development at Norton Healthcare, the UK subsidiary of Ivax Corporation. Mr. Kaye is a director of THV portfolio companies Flynn Pharma and Home Skinovations. Mr. Kaye studied at Brandeis University and the London School of Economics, receiving a B.A, in political science. He received his MBA degree from the University of Southern California.

Warren Roiter was the founder and Senior Partner for more than 30 years of a London-based law firm which specialized in advising pharmaceutical, biotechnology and healthcare companies. During this time he was actively involved in many leading patent and IP cases in Europe. In addition, Mr. Roiter has a wide range of experience of all types of commercial matters involving the healthcare industry and was regarded as “the experts’ expert.” In 2010, Mr. Roiter retired from the practice of law to concentrate his business time on his investing and commercial activities, the principal ones of which include his interests and involvement in Trevi and its investments.